Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

gnancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenström's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 26 trials are currently registered on www.clinicaltrials.gov.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including stat
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... 22, 2014  Recently published clinical studies of Stretta ... substantial database of evidence. This data has led to ... therapy for sufferers of refractory GERD. ... supporting Stretta therapy as a safe and effective GERD ... therapy available to nearly 50 million Americans. The new ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 16, 2011 Reportlinker.com announces that ... is available in its catalogue: ... manufacturing and API sourcing in ... 2011 ...
... -- 3SBio Inc. (NASDAQ: SSRX ) ("3SBio" ... on researching, developing, manufacturing and marketing biopharmaceutical products, today ... and first half ended June 30, 2011. ... Total net revenues increased by 29.0% over the second ...
Cached Medicine Technology:Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 2Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 3Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 4Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 53SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 23SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 33SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 43SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 53SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 63SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 73SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 83SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 93SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 103SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 113SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 123SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 133SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 143SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 153SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 163SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 173SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 183SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 19
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna ... a global biopharmaceutical company focused on,endocrine therapy ... in the,safety study of the Company,s Phase ... (BPH)., Cetrorelix, a novel investigational luteinizing ...
... 14 /PRNewswire-FirstCall/,-- HeartWare Limited (ASX: HTW) today announced that ... Seventh Annual JMP Securities Research,Conference at 9:30 a.m. PT ... is being held at the Ritz-Carlton, San Francisco May ... at the conference will be,available via a link provided ...
... Johns Hopkins doctors has fine-tuned the dosage and timing ... with strokes caused by bleeding within the brain. The ... Conference in Nice, France, has been shown to dramatically ... lethal subset of stroke. , "We,ve gone from what,s ...
... self esteem, SAUSALITO, Calif., May 14 When Peggy ... afraid to go to school,because she had lost her hair ... of her custom-made hair pieces and invited her and her,mother ... -- and raised the money to pay for it., ...
... Revenue Increase and 45% Profit Growth, RIO DE JANEIRO, Brazil, May 13 ... in Brazil, announced today its consolidated,results for the first quarter 2008., ... 1st QUARTER 2008 Highlights, ... March, 33.3% above the same period last ...
... today signed three bills into law:, Senate Bill ... pharmacies, under the supervision of the State Board of,Pharmacy, ... Under the program, drugs may be returned to an ... their original packaging and the,drug expires no sooner than ...
Cached Medicine News:Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 5Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Teen Girl Loses Hair But Gains Support 2Health News:Amil Has Strong Growth With High Profitability 2
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... management of diabetes in order to maintain tight ... effective way to reduce or even prevent diabetes-related ... improving a diabetes patients quality of life, however, ... have been the guiding factors in the development ...
... by the CGMS System Gold can assist ... program based on detailed glycemic profiles. Its ... improve motivation and collaboration with patients.1, ... with all diabetes patients, it may be ...
... Biographer is intended for detecting trends and ... (aged 18 and older) and children/adolescents (aged ... supervise the use of the G2 Biographer ... intended to supplement, not replace, conventional blood ...
Medicine Products: